Expression profiling in canine osteosarcoma: Identification of biomarkers and pathways associated with outcome

BMC Cancer

Volumn 10, Issue , 2010, Pages

  O'Donoghue, Liza E ^a   Ptitsyn, Andrey A ^a   Kamstock, Debra A ^a   Siebert, Janet ^b   Thomas, Russell S ^c   Duval, Dawn L ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b CytoAnalytics   (United States)

^c HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOXORUBICIN; GROWTH HORMONE; SONIC HEDGEHOG PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER;

ACCURACY; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DISEASE FREE INTERVAL; DOG; FEMALE; FOCAL ADHESION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC MARKER; IMMUNE RESPONSE; LIMB AMPUTATION; MALE; NONHUMAN; OSTEOSARCOMA; OXIDATIVE PHOSPHORYLATION; PREDICTION; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; ANIMAL DISEASE; BONE TUMOR; DISEASE FREE SURVIVAL; DISEASE MODEL; DNA MICROARRAY; METABOLISM; METASTASIS; MORTALITY; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE NEOPLASMS; CYCLIC AMP; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; DOGS; FEMALE; MALE; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956815149     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-506     Document Type: Article

References (66)

1. Jaffe N. Adjuvant chemotherapy in osteosarcoma: An odyssey of rejection and vindication. Pediatric and Adolescent Osteosarcoma, Cancer Treatment and Research 2009, 152. New York: Springer, Jaffe N, Bielack SS, Bruland OS.
2. Dernell WS, Ehrhart NP, Straw RC, Vail DM. Tumors of the Skeletal System. Withrow and MacEwen's Small Animal Clinical Oncology 2007, 540-567. St. Louis: Saunders Elsevier, 4.
3. Bacon NJ, Ehrhart NP, Dernell WS, Lafferty M, Withrow SJ. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). JAVMA 2008, 232(10):1504-1510.
4. Chun R, Kurzman ID, Couto CG, Klausner J, Henry C, MacEwen EG. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. Journal of Veterinary Internal Medicine 2000, 14(5):495-498. 10.1111/j.1939-1676.2000.tb02265.x, 11012111.
5. Mauldin GN, Matus RE, Withrow SJ, Patnaik AK. Canine osteosarcoma: Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. Journal of Veterinary Internal Medicine 1988, 2(4):177-180. 10.1111/j.1939-1676.1988.tb00313.x, 3230557.
6. Shapiro W, Fossum T, Kitchell B, Couto C, Theilen G. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. JAVMA 1988, 192(4):507-511.
7. Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). JAVMA 1992, 200(7):995-999.
8. Mueller F, Fuchs B, Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Research 2007, 27(1A):155-164.
9. Thomas R, Wang H, Tsai P, Langford C, Fosmire S, Jubala C, Getzy D, Cutter G, Modiano J, Breen M. Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma. Chromosome Research 2009, 17(3):365-377. 10.1007/s10577-009-9028-z, 19337847.
10. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P, Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009, 10(1):625. 10.1186/1471-2164-10-625, 2803201, 20028558.
11. Sutter NB, Ostrander EA. Dog star rising: the canine genetic system. Nature Reviews Genetics 2004, 5(12):900-910. 10.1038/nrg1492, 15573122.
12. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer 2003, 3(6):453-458. 10.1038/nrc1098, 12778135.
13. Van'tVeer LJ, Weigelt B. Road map to metastasis. Nature Medicine 2003, 9(8):999-1000.
14. van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
15. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nature Chemical Biology 2006, 2(12):689-700. 10.1038/nchembio840, 17108987.
16. Varmus H. The New Era in Cancer Research. Science 2006, 312(5777):1162-1165. 10.1126/science.1126758, 16728627.
17. Jeys L, Grimer R, Carter S, Tillman R, Abudu A. Post operative infection and increased survival in osteosarcoma patients: are they associated?. Annals of Surgical Oncology 2007, 14(10):2887-2895. 10.1245/s10434-007-9483-8, 17653803.
18. Lascelles B, Dernell W, Correa M, Lafferty M, Devitt C, Kuntz C, Straw R, Withrow S. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Annals of Surgical Oncology 2005, 12(12):1073-1083. 10.1245/ASO.2005.01.011, 16252138.
19. Affymetrix Guide to Probe Logarithmic Intensity Error (PLIER) Estimation 2005, Affymetrix.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
21. Weinstein JN, Myers TG, O'Connor PM, Friend SH AJF, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Osdol W, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275(5298):343-349. 10.1126/science.275.5298.343, 8994024.
22. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, Roskin KM, Schwartz M, Sugnet CW, Thomas DJ, Weber RJ, Haussler D, Kent WJ. The UCSC Genome Browser Database. Nucl Acids Res 2003, 31(1):51-54. 10.1093/nar/gkg129, 165576, 12519945.
23. Kent WJ. BLAT---The BLAST-Like Alignment Tool. Genome Research 2002, 12(4):656-664. 187518, 11932250.
24. Thomson SAM, Kennerly E, Olby N, Mickelson JR, Hoffmann DE, Dickinson PJ, Gibson G, Breen M. Microarray analysis of differentially expressed genes of primary tumors in the canine central nervous system. Veterinary Pathology 2005, 42:550-558. 10.1354/vp.42-5-550, 16145201.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
26. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 2001, 29(9):e45. 10.1093/nar/29.9.e45, 55695, 11328886.
27. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research 2002, 30(9):e36. 10.1093/nar/30.9.e36, 113859, 11972351.
28. Ptitsyn A, Weil M, Thamm D. Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics 2008, 9(Suppl 9):S8. 10.1186/1471-2105-9-S9-S8, 2537559, 18793472.
29. Patel S, Lyons-Weiler J. caGEDA: a web application for the integrated analysis of global gene expression patterns in cancer. Applied Bioinformatics 2004, 3(1):49-62. 10.2165/00822942-200403010-00007, 16323966.
30. Dennis G, Sherman B, Hosack D, Yang J, Gao W, Lane HC, Lempicki R. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology 2003, 4(5):P3. 10.1186/gb-2003-4-5-p3, 12734009.
31. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 2008, 4(1):44-57.
32. Witten I, Frank E. Data Mining: Practical machine learning tools and techniques 2005, San Francisco: Morgan Kaufmann, 2.
33. Depeursinge A, Iavindrasana J, Hidki A, Cohen G, Geissbuhler A, Platon A, Poletti P, Müller H. Comparative performance analysis of state-of-the-art classification algorithms applied to lung tissue categorization. Journal of Digital Imaging 2008,
34. Lemm I, Ross J. Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant. Molecular and Cellular Biology 2002, 22(12):3959-3969. 10.1128/MCB.22.12.3959-3969.2002, 133878, 12024010.
35. Noubissi FK, Elcheva I, Bhatia N, Shakoori A, Ougolkov A, Liu J, Minamoto T, Ross J, Fuchs SY, Spiegelman VS. CRD-BP mediates stabilization of [beta]TrCP1 and c-myc mRNA in response to [beta]-catenin signalling. Nature 2006, 441(7095):898-901. 10.1038/nature04839, 16778892.
36. Vikesaa J, Hansen TVO, Jønson L, Borup R, Wewer UM, Christiansen J, Nielsen FC. RNA-binding IMPs promote cell adhesion and invadopodia formation. The EMBO Journal 2006, 25(7):1456-1468. 10.1038/sj.emboj.7601039, 1440323, 16541107.
37. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of Insulin-Like Growth Factor II mRNA-binding proteins represses translation in late development. Molecular and Cellular Biology 1999, 19(2):1262-1270. 116055, 9891060.
38. Huttelmaier S, Zenklusen D, Lederer M, Dictenberg J, Lorenz M, Meng X, Bassell GJ, Condeelis J, Singer RH. Spatial regulation of [beta]-actin translation by Src-dependent phosphorylation of ZBP1. Nature 2005, 438(7067):512-515. 10.1038/nature04115, 16306994.
39. Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD, Zeng K, Thomssen C, Hauptmann S, Huttelmaier S. Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. Oncogene 2007, 26(54):7584-7589. 10.1038/sj.onc.1210563, 17546046.
40. Dimitriadis E, Trangas T, Milatos S, Foukas PG, Gioulbasanis I, Courtis N, Nielsen FC, Pandis N, Dafni U, Bardi G, Ioannidis P. Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. International Journal of Cancer 2007, 121(3):486-494.
41. Yang Y, Tian X, Xie X, Zhuang Y, Wu W, Wang W. Expression and regulation of hedgehog signaling pathway in pancreatic cancer. Langenbeck's Archives of Surgery 2009,
42. Minuto F, Palermo C, Arvigo M, Barreca AM. The IGF system and bone. Journal of Endocrinological Investigation 2005, 28(8 Suppl):8-10.
43. Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, Lock CB, Herzenberg LA, Steinman L, Herzenberg LA. Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proceedings of the National Academy of Sciences 2000, 97(6):2680-2685.
44. Bigl M, Jandrig B, Horn L-C, Eschrich K. Aberrant methylation of human L- and M-fructose 1,6-bisphosphatase genes in cancer. Biochemical and Biophysical Research Communications 2008, 377(2):720-724. 10.1016/j.bbrc.2008.10.045, 18938139.
45. Lyon RC, Johnston SM, Panopoulos A, Alzeer S, McGarvie G, Ellis EM. Enzymes involved in the metabolism of [gamma]-hydroxybutyrate in SH-SY5Y cells: Identification of an iron-dependent alcohol dehydrogenase ADHFe1. Chemico-Biological Interactions 2009, 178(1-3):283-287. 10.1016/j.cbi.2008.10.025, 19013439.
46. Kobayashi S, Fukuhara A, Taguchi T, Matsuda M, Tochino Y, Otsuki M, Shimomura I. Identification of a new secretory factor, CCDC3/Favine, in adipocytes and endothelial cells. Biochemical and Biophysical Research Communications 2010, 392(1):29-35. 10.1016/j.bbrc.2009.12.142, 20043878.
47. Bruheim S, Xi Y, Ju J, Fodstad O. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clinical Cancer Research 2009, 15(23):7161-7169. 10.1158/1078-0432.CCR-08-2816, 19920113.
48. Chionia A-M, Brackenburyb WJ, Calhounb JD, Isomb LL, Djamgoza MBA. A novel adhesion molecule in human breast cancer cells: Voltage-gated Na+ channel β1 subunit. The International Journal of Biochemistry & Cell Biology 2009, 41(5):1216-1227.
49. Yao L, Zhang J, Liu X. NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochimica et Biophysica Sinica 2008, 40(7):625-635. 10.1111/j.1745-7270.2008.00434.x, 18604454.
50. Squire J, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, Zielenska M. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003, 38(3):215-225. 10.1002/gcc.10273, 14506695.
51. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. International Journal of Cancer 2008, 123(9):2080-2086.
52. Kim YJ, Yoon SY, Kim J-T, Choi SC, Lim J-S, Kim JH, Song EY, Lee HG, Choi I, Kim JW. NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. International Journal of Cancer 2009, 124(1):7-15.
53. Kim A, Kim M-J, Yang Y, Kim JW, Yeom YI, Lim J-S. Suppression of NF-{kappa}B activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis 2009,
54. Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, Wu Y, Ji S, Zhang Y, Yang A, Han H, Yao L. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Research 2008, 36(16):5335-5349. 10.1093/nar/gkn504, 2532733, 18689861.
55. Kim Y-J, Yoon SY, Kim J-T, Song EY, Lee HG, Son HJ, Kim SY, Cho D, Choi I, Kim JH, Kim JW. NDRG2 expression decreases with tumor stages and regulates TCF/{beta}-catenin signaling in human colon carcinoma. Carcinogenesis 2009, 30(4):598-605. 10.1093/carcin/bgp047, 2664458, 19237607.
56. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X-Y, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proceedings of the National Academy of Sciences 2008, 105(48):18782-18787.
57. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Gesto DD, Marra M, Romano M, Sorrentino A, Sorvillo L, Spina A, Illiano G. Protein kinase A as a biological target in cancer therapy. Expert Opinion on Therapeutic Targets 2009, 13(1):83-92. 10.1517/14728220802602349, 19063708.
58. Day TF, Yang Y. Wnt and hedgehog signaling pathways in bone development. The Journal of Bone and Joint Surgery 2008, 90(Suppl 1):19-24. 10.2106/JBJS.G.01174, 18292352.
59. Katoh Y, Katoh M. Comparative genomics on HHIP family orthologs. International Journal of Molecular Medicine 2006, 17(2):391-395.
60. Tojo M, Kiyosawa H, Iwatsuki K, Kaneko F. Expression of a sonic hedgehog signal transducer, hedgehog-interacting protein, by human basal cell carcinoma. British Journal of Dermatology 2002, 146(1):69-73. 10.1046/j.1365-2133.2002.04583.x, 11841368.
61. Olsen C, Hsu P-P, Glienke J, Rubanyi G, Brooks A. Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors. BMC Cancer 2004, 4(1):43-53. 10.1186/1471-2407-4-43, 512291, 15294024.
62. Man T-K, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong K-K, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Research 2005, 65(18):8142-8150. 10.1158/0008-5472.CAN-05-0985, 16166288.
63. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, LaFleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, MacDonald TJ, Gorlick R, Stephan DA. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Research 2005, 65(5):1748-1754. 10.1158/0008-5472.CAN-04-2463, 15753370.
64. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. International Journal of Oncology 2004, 24(3):647-655.
65. Walters DK, Steinmann P, Langsam B, Schmutz S, Born W, Fuchs B. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Research 2008, 28(2A):673-680.
66. Selvarajah GT, Kirpensteijn J, Wolferen M, Rao NA, Fieten H, Mol JA. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Molecular Cancer 2009, 8:72-90. 10.1186/1476-4598-8-72, 2746177, 19735553.